XML 98 R26.htm IDEA: XBRL DOCUMENT v3.25.2
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of segment reporting information
               
    Year ended
December 31,
 
    2024     2023  
Total revenues(b)   $ 168,721     $ 110,748  
Less:                
Cost of revenues     36,593       25,688  
Research and development expense (excluding stock-based compensation expense):                
Clinical trials     87,492       80,569  
HALO Design     534,527       336,870  
SYNC project     102,565       -  
Other research and development(a)     66,300       4,372  
General and administrative expense (excluding share-based compensation expense)     2,553,459       2,367,821  
Amortization     15,107       3,751  
Stock-based compensation expense     3,560,509       2,413,375  
Professional fees     966,815       574,598  
Interest (income) expense, net     (3,193 )     38,835  
Equity in net income from equity method investees     (4,851 )     -  
Other income     (139,420 )     (1,086,422 )
Segment net loss     (7,607,182 )     (4,648,709 )
                 
Reconciliation of net loss                
Adjustments and reconciling items     -       -  
Consolidated net loss   $ (7,607,182 )   $ (4,648,709 )

 

 
(a) Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs.
(b) Revenue concentrations are reflected in Note 9